A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Trial Profile

A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Presatovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 14 Apr 2018 Primary endpoint (Time-Weighted Average Change in log10 Viral Load from Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set)has not been met as per the results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 14 Apr 2018 Primary endpoint (Time-Weighted Average Change in log10 Viral Load from Day 1/Baseline Through Day 7 in a Subset of Participants in the Full Analysis Set Whose Duration of RSV Symptoms Prior to the First Dose of Study Drug is Median) has not been met as per the results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 14 Apr 2018 Results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top